Lioresal 5mg/5ml Oral Solution

  • Name:

    Lioresal 5mg/5ml Oral Solution

  • Company:
    info
  • Active Ingredients:

    Baclofen

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 28/11/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 25/11/2019

Click on this link to Download PDF directly

Novartis Ireland Limited

Novartis Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Aclasta 5 mg solution for infusion Active Ingredients Zoledronic acid monohydrate
Medicine Name Afinitor Tablets Active Ingredients Everolimus
Medicine Name Aimovig Active Ingredients Erenumab
Medicine Name Atriance 5 mg/ml solution for infusion Active Ingredients Nelarabine
Medicine Name Azarga 10mg/ml + 5mg/ml eye drops, suspension Active Ingredients Brinzolamide, Timolol Maleate
Medicine Name Azopt 10mg/ml eye drops suspension Active Ingredients Brinzolamide
Medicine Name Cataflam 50 mg Coated Tablets Active Ingredients Diclofenac Potassium
Medicine Name Certican Tablets Active Ingredients Everolimus
Medicine Name CILOXAN 3 mg/ml ear drops, solution Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Co-Diovan 160 mg/12.5 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 160mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 80mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Cosentyx 150 mg solution for injection in pre-filled pen Active Ingredients secukinumab
Medicine Name Desferal 500mg Vials Active Ingredients Desferrioxamine Mesylate
Medicine Name Diovan 160 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 320mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 3mg/ml Oral Solution Active Ingredients Valsartan
Medicine Name Diovan 40 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 80 mg film-coated tablets Active Ingredients Valsartan
Medicine Name DuoTrav Eye Drops Solution Active Ingredients Timolol Maleate, Travoprost
Medicine Name Entresto 24mg/26mg, 49mg/51mg and 97mg/103mg film-coated tablets Active Ingredients Sacubitril, Valsartan
Medicine Name Estradot Transdermal Patches Active Ingredients Estradiol Hemihydrate
Medicine Name Eucreas 50mg / 850mg and 50mg / 1000mg film-coated tablets Active Ingredients Metformin Hydrochloride, Vildagliptin
1 - 0 of 116 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 28 November 2019 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 27 November 2019 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 25 November 2019 SmPC

Reasons for updating

  • Other

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 25 November 2019 SmPC

Reasons for updating

  • Other

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 25 November 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 11 November 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 11 November 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 8 April 2019 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 14 November 2018 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 16 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

MAT transfer

Updated on 25 May 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 21 February 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 21 February 2017 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 22 December 2014 PIL

Reasons for updating

  • Change of manufacturer
  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 15 October 2014 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 15 October 2014 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2 has been updated to include the sentence: Excipient with known effect: 61.0 mg wheat starch per tablet.
Section 4.2 has been revised to include a statement on discontinuation of treatment and to change to dosage from "3 divided doses" to "between 2 and 4 divided doses". A paragraph on "hepatic impairment" and on "patients with spastic states of cerebral origin" have bee included.
Section 4.4 has been revised to include the sentence "Since unwanted effects are more likely to occur, a cautious dosage schedule should beadopted in elderly and patients with spasticity of cerebral origin (see section 4.2 posology and method of administration)."
Section 4.5 has been updated with additional interactions for Levodopa/Dopa Decarboxylase (DDC) inhibitor (Carbidopa) and Lithium.
Section 4.6 has been revised to include information on fertility and women of child-bearing potential.
Section 4.7 has been updated to add statement on "posture and balance".
Section 4.8 has been revised with additional ADRs and information for reporting of ADRs to the HPRA.
Section 4.9 has been updated to remove the section regarding ingestion of activated charcoal.
Section 5.1 has been revised to include a more detailed Mechanism of Action.
Section 5.2 has been updated to add sections on paediacric patients and patients with hepatic and renal impairment.
Section 5.3 has been revised to include information on reproductive toxicity and mutagenicity/carcinogenicity.

Updated on 3 July 2013 PIL

Reasons for updating

  • Change of manufacturer

Updated on 27 May 2013 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 6.5 has been updated to reflect a new primary packaging container.

Updated on 20 February 2013 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 7 February 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration

Updated on 1 September 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2, additional detail about excipients has been included.
In section 4.1, information relating to paediatric population has been added
In section 4.2, section has been updated due to the paediatric indication.
In section 4.4, new information on renal impairment, abrupt withdrawal and paediatric population have been added.
In section 4.6, information on withdrawal reaction has been included.
In section 4.8, "urticaria" has been added as a hepatobiliary disorder (frequency unknown).
In section 4.9, new information added: convulsions, EEG changes (burst suppression pattern and triphasic waves), or cardiac arrhythmias. Haemodialysis (sometimes unscheduled) may be useful in severe poisoning associated with renal failure (see section 4.4 Special warnings and precautions for use).
In section 6.1, E numbers have been added for relevant excipients.
In section 6.2, the following statement has been added:This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
In section 6.3, the following statement has been added: After dilution, the product may be stored at room temperature for up to 14 days.
In section 6.4, storage conditions have been updated.
In section 6.6, reference to storage at room temperature for up to 14 days has been removed.

Updated on 14 July 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2 it states: The solution contains  1 mg/1 ml baclofen, 1.4 mg/ml methyl parahydroxybenzoate, 0.14 mg/ml propyl parahydroxybenzoate  and 1.62 mg/ml sodium 
In section 4.2 the dosing for adults and children has been updated as well as for patients with renal impairment and elderly.
In section 4.4 new sub-headings have been added and a new section on renal impairment included.
In section 4.5 the last paragraph has been removed as this was duplicate information.
In section 4.9 new information on haemodialysis has been added as well as some additional symptoms of overdose.
In section 6.1 E numbers have been added for some excipients.
In section 6.2 Incompatabilities included.
In section 6.3 Information on dilution added.
In section 6.4 the storage conditions have been updated to include reference to protection from light.
In section 6.6 reference to storage at room temperature has been removed.

Updated on 14 July 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to information about pregnancy or lactation
  • Change to further information section

Updated on 3 September 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 3 September 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 10 April 2006 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 10 March 2006 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 14 April 2005 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)